Galenica: nine-month sales up 5.7%, full-year guidance held
Galenica's nine-month sales rose 5.7% to CHF 3,172.0 million, and 2026 guidance was confirmed, according to a TradingView report.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, sales at Swiss company Galenica rose 5.7% in January to September, reaching CHF 3,172.0 million. Growth was led by the pharmacy segment and home care services.
The company confirmed its 2026 guidance for both sales and adjusted EBIT. However, wholesale growth in the third quarter was temporarily held back by the migration to a new ERP system.
why it matters
For the market, the key point is that the company kept its annual outlook despite a temporary slowdown in wholesale. The report describes the constraint as temporary, so the news is largely neutral for the shares and of moderate significance for the pharmaceutical distribution sector.
market impact
Galenica shares: confirmed annual guidance offset by a temporary wholesale slowdown
tags
instruments
sources
- GALE: Sales grew 5.7%; FY guidance held as ERP migration temporarily slowed wholesale growth — TradingView, 22 October 2026 at 04:54 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗